mazindol (sanorex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

42-548 | mazanor | mazildene | mazindol | mazindolo | mazindolum | sanorex | teronac

Organizations (8)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (2)


 

Muscular Dystrophy, Duchenne (approved 1986)

Obesity (approved 1973)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Cocaine-Related Disorders (Phase 2)

Disorders of Excessive Somnolence (Phase 2)

Narcolepsy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue